Catherine Moukheibir

Catherine Moukheibir was appointed to the Board as a Non-Executive Director in December 2021.

Over the course of her career, Ms Moukheibir has served in senior executive roles and board positions including at Kymab Limited, Innate Pharma S.A, Ablynx N.V, Genkyotex S.A, MedDay Pharmaceuticals (Chairman and CEO), Zealand Pharma A/S, Zeltia S.A., and Creabilis SA. Prior to that, she was the CFO of Movetis N.V, overseeing the company’s IPO on Euronext and subsequent sale to Shire Pharmaceuticals plc. She started her career in investment banking and capital markets working in the US and London. Ms Moukheibir holds an MBA and a Masters in Economics from Yale University.

Ms Moukheibir has extensive international experience in finance, capital markets and life sciences and is currently serving as a Non-Executive board member with various companies, both listed (Biotalys NV, Ironwood Pharmaceuticals, Inc and MoonLake ImmunoTherapeutics), and privately owned (CMR Surgical Limited, Asceneuron SA. DNA Script SAS and Noema Pharma AG).

Catherine Moukheibir will not be standing for re-election at the forthcoming Annual General Meeting in June 2024.

Committee Membership:

• Audit Committee

Relevant Skills:

• Corporate finance
• Corporate strategy